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Lafora progressive myoclonus epilepsy is a fatal neurodegenerative disorder caused by defects in the function of at least
two proteins: laforin, a dual-specificity protein phosphatase, and malin, an E3-ubiquitin ligase. In this study, we report
that a functional laforin–malin complex promotes the ubiquitination of AMP-activated protein kinase (AMPK), a
serine/threonine protein kinase that acts as a sensor of cellular energy status. This reaction occurs when any of the three
AMPK subunits (, , and ) are expressed individually in the cell, and it also occurs on AMPK when it is part of a
heterotrimeric complex. We also report that the laforin–malin complex promotes the formation of K63-linked ubiquitin
chains, which are not involved in proteasome degradation. On the contrary, this modification increases the steady-state
levels of at least AMPK subunit, possibly because it leads to the accumulation of this protein into inclusion bodies.
These results suggest that the modification introduced by the laforin–malin complex could affect the subcellular
distribution of AMPK subunits.
INTRODUCTION
Lafora progressive myoclonus epilepsy (Lafora disease
[LD], OMIM 254780) is a fatal autosomal recessive neurode-
generative disorder characterized by the presence of glyco-
gen-like intracellular inclusions named Lafora bodies (for
reviews, see Delgado-Escueta, 2007; Gentry et al., 2009). LD
initially manifests during adolescence with generalized ton-
ic-clonic seizures, myoclonus, absences, drop attacks, and
visual hallucinations. As the disease proceeds, a rapidly
progressive dementia with apraxia, aphasia and visual loss
ensues, leading patients to a vegetative state and death,
usually within the first decade from onset of the first symp-
toms (Ganesh et al., 2006; Delgado-Escueta, 2007). Mutations
causing LD have been identified in two genes, EPM2A (Mi-
nassian et al., 1998; Serratosa et al., 1999) and EPM2B
(NHLRC1) (Chan et al., 2003), although there is evidence for
a third locus (Chan et al., 2004). EPM2A encodes laforin, a
dual-specificity phosphatase with a functional carbohydrate
binding domain at the N terminus (Minassian et al., 2000;
Wang et al., 2002). EPM2B encodes malin, an E3-ubiquitin
ligase with a RING finger domain at the N terminus and six
NCL1, HT2A, and LIN-41 domains in the C-terminal region
that are involved in protein–protein interactions (Chan et al.,
2003; Gentry et al., 2005; Lohi et al., 2005). We and others
have recently described that laforin interacts physically with
malin and that laforin recruits specific substrates to be ubi-
quitinated by malin (Gentry et al., 2005; Lohi et al., 2005;
Solaz-Fuster et al., 2008). An alternative function of laforin
on glycogen homeostasis also has been described (Worby et
al., 2006; Tagliabracci et al., 2007). In this case, laforin acts as
a phosphatase of complex carbohydrates, and it has been
proposed that this function might be necessary for the main-
tenance of normal cellular glycogen (Gentry et al., 2007;
Tagliabracci et al., 2008).
Our group has recently described that the activity of the
laforin–malin complex is regulated by the AMP-activated
protein kinase (AMPK) (Solaz-Fuster et al., 2008). AMPK is a
serine/threonine protein kinase that acts as a sensor of cel-
lular energy status. AMPK is a heterotrimer of three differ-
ent subunits: , , and . AMPK is the catalytic subunit of
the AMPK complex; it contains a highly conserved kinase
domain (KD) located at the N terminus of the protein, fol-
lowed by an autoinhibitory domain (Pang et al., 2007) and a
C-terminal domain required for interaction with the AMPK
subunit (Xiao et al., 2007). Two isoforms of the catalytic
subunit have been described, namely, 1 and 2. The
AMPK subunit contains four tandem repeats of a structural
module called a CBS motif, described initially in the enzyme
cystathionine--synthase (Bateman, 1997), involved in AMP
binding (Scott et al., 2004; Xiao et al., 2007). Three isoforms of
the -subunit, named 1, 2, and 3, have been described.
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Finally, the AMPK subunit functions as a scaffold to as-
semble the  and  subunits and also may affect the subcel-
lular localization and substrate specificity of the complex.
Two isoforms of the -subunit (1 and 2) have been de-
scribed; they differ somewhat in their N-terminal regions,
but they interact with the same efficiency with AMPK
and AMPK subunits (Gimeno-Alcaniz and Sanz, 2003;
Thornton et al., 1998). AMPK activity is regulated by allo-
steric activation by AMP and by the phosphorylation of
Thr172 residue within the catalytic domain of the  subunit
by upstream kinases (Sanz, 2008). Because we described that
laforin interacts with subunits of the AMPK complex, we
decided to analyze whether the laforin–malin complex could
promote the ubiquitination of the AMPK subunits, in a
similar way to what we described for another substrate of
the laforin–malin complex, the type 1 protein phosphatase
(PP1) glycogenic targeting subunit protein targeting to gly-
cogen R5 (R5/PTG) (Solaz-Fuster et al., 2008).
Although protein ubiquitination was first described as a
mechanism for targeting proteins for rapid proteasomal deg-
radation, in recent years other functions of ubiquitination
have been delineated. Ubiquitination occurs by the addition
of ubiquitin monomers to a lysine side chain of a target
protein by a process involving three different enzymes: E1-
ubiquitin–activating, E2-ubiquitin—conjugating, and E3-
ubiquitin ligase enzymes. This reaction either results in the
attachment of a single ubiquitin moiety (monoubiquitina-
tion) or in the subsequent addition of further molecules of
ubiquitin on the first ubiquitin (polyubiquitination). In the
latter case, new ubiquitin moieties are linked to previous
moieties by using internal lysines of ubiquitin. It is now
becoming clear that the basis for the multiple functions of
ubiquitination (proteolytic and nonproteolytic) relies in part
on the type of linkages in the polyubiquitin chains. Among
the seven lysines present in the ubiquitin molecule, K48- and
K63-linked polyubiquitin chains are the most frequent mod-
ifications detected so far. Although K48-linked ubiquitin
chains generally target proteins for proteasomal degrada-
tion, K63-linked ubiquitin chains may be involved in other
functions mostly not connected with protein degradation
(Ikeda and Dikic, 2008; Deshaies and Joazeiro, 2009).
In this article, we report that laforin and malin form a
functional complex with E3-ubiquitin ligase activity that is
able to ubiquitinate the three AMPK subunits (, , and )
when they are expressed individually in the cells, and also
the AMPK subunit when it is part of the endogenous
heterotrimeric complex. The laforin–malin complex intro-
duces K63-linked ubiquitin chains into proteins, mediating
functions that are different from targeting them to the pro-
teasome for degradation.
MATERIALS AND METHODS
Plasmids
Plasmid pCMVmyc-AMPK2 KD was constructed by amplifying by poly-
merase chain reaction (PCR), using oligonucleotides 2-11 and 2-2 (Table 1)
and plasmid pCMVmyc-AMPK2 as template, a fragment containing the
kinase domain (residues 1–312) of AMPK2. The fragment was digested with
EcoRI and SalI and subcloned into plasmid pCMVmyc (BD Biosciences, San
Jose, CA). Similarly, a fragment containing the regulatory domain of
AMPK2 (residues 313–552) was amplified by PCR using oligonucleotides
2-RD and 2-4 (Table 1), digested with EcoRI and SalI, and subcloned into
plasmid pCMVmyc. Plasmid pCMVmyc-AMPK1 was obtained by digesting
plasmid pACT2-AMPK1 (Gimeno-Alcaniz and Sanz, 2003) with SfiI and
BglII and subcloning the resulting fragment into pCMVmyc. To construct
plasmid pCMVmyc-AMPK2 glycogen binding domain (GBD), oligonucleo-
tides 2-7 and 2-6 (Table 1) were used to amplify by PCR an N-terminal
fragment of AMPK2 (residues 1–185) containing the GBD, using pCMVmyc-
AMPK2 as template; the fragment was digested with EcoRI and XhoI and
subcloned into plasmid pCMVmyc. Similarly, a fragment containing the
C-terminal part of AMPK2 (residues 186–271) was amplified by PCR using
oligonucleotides 2-9 and 2-2 (Table 1), digested with EcoRI and SalI, and
subcloned into plasmid pCMVmyc to obtain plasmid pCMVmyc-AMPK2
ASC. Finally, plasmid pcDNA4/His-AMPK2 was constructed by digesting
plasmid pCMVmyc-AMPK2 with BamHI and subcloning the resulting frag-
ment into plasmid pcDNA4/HisMaxA (Invitrogen, Carlsbad, CA).
Plasmid pFLAG-CIDEA was obtained in several steps. First, CIDEA cDNA
was amplified by PCR from a human skeletal muscle cDNA library (Clontech,
Mountain View, CA) using oligonucleotides CIDEA-1 and CIDEA-2 (Table 1).
The fragment was digested with EcoRI and XhoI and subcloned into plasmid
pFLAG-CMV (Sigma-Aldrich, St. Louis, MO).
All plasmids containing a fragment obtained by PCR were sequenced to
confirm that the Taq polymerase had not included undesired mutations. Other
plasmids used in this study were pCMV-AMPK1, pCMVmyc-AMPK2,
pCMVmyc-AMPK2, and pCMVmyc-AMPK1 (Solaz-Fuster et al., 2006);
pcDNA3-HA-malin, pCMV-HA-laforin, and pCMV-myc-R5/PTG (Solaz-Fus-
ter et al., 2008); pCMV-His6xUbiq (from Dr. M. Rodriguez, Proteomics Unit,
CIC-BioGUNE, Vizcaya, Spain); pCMV-His6xUbiq K48R and pCMV-
His6xUbiq K63R (from Dr. Christine Blattner, Institute of Toxicology and
Genetics, Karlsruhe Institute of Technology, Karlsruhe, Germany); pRCc/
CMV-p53 (from Dr. A. Dickmanns, University of Go¨ttingen, Go¨ttingen, Ger-
many); and pCMV-Mdm2 (Worby et al., 2008) (from Dr. M. Gentry, University
of Kentucky, Lexington, KY).
Analysis of In Vivo Ubiquitination
To study ubiquitination in intact cells, human embryonic kidney (HEK)293
cells were transfected with plasmids pCMV-His6xUbiq (encoding a modified
ubiquitin, tagged with 6 His residues); pCMVmyc plasmids encoding the
protein of interest; and, when indicated, pcDNA3-HA-malin and pCMV-HA-
laforin plasmids, by using the Lipofectamine 2000 reagent (Invitrogen), ac-
cording to the manufacturer’s instructions. After 36 h of transfection, cells
were lysed in buffer A (6 M guanidinium-HCl, 0.1 M sodium phosphate, and
0.1 M Tris-HCl, pH 8.0). Four milligrams of protein of a clarified extract (CE;
12,000  g for 15 min) was incubated in 100 l of TALON column (Clontech)
in the presence of 10 mM imidazole, for 3 h at room temperature on a rocking
platform, to purify His-tagged proteins. The column was then successively
washed with 2 ml each of buffer B (buffer A plus 10 mM imidazole), buffer C
(buffer B but with 8 M urea instead of 6 M guanidinium-HCl), and four more
times with buffer C adjusted to pH 6.0. Bound proteins (bound) were eluted
with 50 l of 2 Laemmli’s sample buffer and analyzed by Western blotting
using appropriated antibodies. When indicated, plasmids pCMV-His6xUbiq
K48R and pCMV-His6xUbiq K63R were used in the assay instead of pCMV-
His6xUbiq.
Table 1. Oligonucleotides used in this study (new restriction sites are underlined)
Name Sequence
2-2 5-GCGGGTCGACTTAGTATAAACTGTTCATCACTTCTGATTC-3
2-4 5-GCCGGTCGACTTTCAACGGGCTAAAGCAGTGATAAG-3
2-11 5-CTTCGAATTCGAATGGCTGAGAAGCAGAAGCACG-3
2-RD 5-GGGCGAATTCGGAGTGGTGACCCTCAAGACCAGC-3
2-2 5-CTCGGTCGACTTCAAATGGGCTTGTATAGCAGA-3
2-6 5-CGAGCTCGAGAGGGGTGAGCTGGAAAGGTCTCT-3
2-7 5-ACTGGAATTCGAATGGGAAACACCACCAGCGAC-3
2-9 5-ACTCGAATTCCAGGGCCTTATGGTCAAGAA-3
CIDEA-1 5-ACTGGAATTCGAATGGAGGCCGCCCGGGACTATGC-3
CIDEA-2 5-CGAGCTCGAGAGTCCACACGTGAACCTGCCCTTGG-3
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Immunoblotting
Forty micrograms of total protein from the clarified extracts prepared as
described above were analyzed by SDS-polyacrylamide gel electrophoresis
(PAGE) and Western blotting using appropriate antibodies: anti-myc (Sigma-
Aldrich); anti-p53 (Exbio, Vestec Czech Republic); anti-AMPK total (Cell
Signaling Technology, Danvers, MA); anti-AMPK total (Cell Signaling Tech-
nology); anti-panAMPK, anti-AMPK1 (Cell Signaling Technology); anti--
tubulin (Sigma-Aldrich); anti-ubiquitin conjugates (BIOMOL Research Labo-
ratories, Plymouth Meeting, PA); and anti-K48 ubiquitin chain and anti-K63
ubiquitin chain conjugates (a generous gift of Genentech, South San Francisco,
CA) (Newton et al., 2008).
Analysis of the Degradation Rates of Free AMPK
Subunits
HEK293 cells were transfected with the appropriated combination of plas-
mids. Twenty-four hours after transfection, cells were treated with 355 M
cycloheximide (CHX), and, at the indicated times (from 0 to 12 h), aliquots
were taken from the cultures and cell extracts (25 g) were analyzed by
SDS-PAGE and Western blotting using anti-myc antibodies. The same ex-
tracts were analyzed using anti-tubulin antibodies as a loading control. West-
ern blots were analyzed by densitometry using an LAS-3000 electronic reader
(Fujifilm, Tokyo, Japan) and the Image Gauge, version 4.0 software (Fujifilm).
The levels of the corresponding myc-AMPK subunit with respect to the levels
of tubulin at each time point are expressed as a percentage of the values at
time 0.
Immunofluorescence and Confocal Microscopy
HEK293 cells transfected with the appropriate plasmids were grown on plates
containing coverslips. Cells were fixed with 4% paraformaldehyde in phos-
phate-buffered saline (PBS) for 10 min, and then the fixation was stopped with
10 mM glycine for 5 min. Cells were permeabilized with 0.5% Triton X-100 in
PBS for 5 min. Samples were washed three times with PBS and blocked with
10% fetal bovine serum, 5% nonfat dried milk, and 0.1% Triton X-100 in PBS
for 5 h at 4°C. Samples were then incubated overnight at 4°C with a 1/200
dilution of anti-AMPK total (Cell Signaling Technology) with or without
anti-laforin (1/2000) in blocking solution. Samples were washed five times
with PBS during 1 h at room temperature and incubated again with a 1/500
dilution of appropriated fluorescent-labeled secondary antibodies (anti-rabbit
Alexa-Fluor 488 and anti-mouse Texas Red; Invitrogen). Nuclei were stained
with a 1/500 dilution of a Tropro3 fluorescent probe in PBS for 10 min.
Finally, samples were washed again with PBS and mounted on slices using
Fluoromount G. Images were acquired for 2 m slices with a TCS/SP2
confocal microscope (Leica, Wetzlar, Germany) using a 63 oil immersion
objective. Images were treated with the ImageJ 1.43c software (Wayne Ras-
band, National Institutes of Health, Bethesda, MD). More than 100 green cells
(therefore containing AMPK) were analyzed for each condition and used to
determine the presence or absence or large intracellular inclusions. Because in
cotransfection experiments some of the green cells may not contain the rest of
the plasmids, the quantification of cells containing large inclusions could be
underestimated because in this case the cells were considered as punctuated
pattern of AMPK.
Statistical Analyses
Values are given as means  SD of at least three independent experiments.
Differences between groups were analyzed by two-tailed Student’s t tests. The
significance has been considered at *p  0.05 and **p  0.01, as indicated in
each case.
RESULTS
The Laforin–Malin Complex Promotes the Ubiquitination
of AMPK Subunits
We have recently described that the activity of the laforin–
malin complex is modulated by the AMPK complex and that
AMPK interacted physically with laforin (Solaz-Fuster et al.,
2008). Because we also described that the laforin–malin com-
plex interacted with the PP1 glycogenic-targeting subunit
R5/PTG and promoted its ubiquitination (Solaz-Fuster et al.,
2008), we decided to analyze whether the laforin–malin
complex was also able to promote the ubiquitination of the
AMPK subunits. With this aim, we set up an assay for the
analysis of ubiquitinated proteins based on the expression in
mammalian HEK293 cells of a 6xHis-tagged version of ubiq-
uitin (Kaiser and Tagwerker, 2005). Cell extracts were made
in the presence of the chaotropic agent guanidinium chlo-
ride, to inhibit deubiquitinating enzymes, and ubiquitinated
proteins were purified by metal-affinity chromatography.
This purified fraction (bound material) was analyzed by
SDS-PAGE and Western blotting, using specific antibodies
against the protein of interest (Figure 1A). We then coex-
pressed in these HEK293 cells individual AMPK subunits
and laforin, malin, or a combination of laforin and malin. As
shown in Figure 1B, we observed an efficient ubiquitination
of the three individual AMPK subunits tested, i.e., AMPK2,
-2, and -1 but only when we coexpressed these subunits
with a combination of laforin and malin. For AMPK2 and
AMPK1, we also detected a minor modification when only
laforin was overexpressed, perhaps because it can force
endogenous malin to carry out the corresponding ubiquiti-
nation. These results confirmed our previous observation
that both laforin and malin are needed to form a functional
complex, in which laforin recruits putative substrates to be
modified by the E3-ubiquitin ligase activity of malin (Solaz-
Fuster et al., 2008).
To check the possibility that the ubiquitination of the
AMPK subunits was nonspecific and could be carried out by
the overexpression of any E3-ubiquitin ligase, we repeated
the experiment expressing Mdm2, another RING E3-ubiq-
uitin ligase involved in the ubiquitination of p53 (Brady et
al., 2005). As shown in Figure 1C, compared with the
laforin–malin complex, Mdm2 did not carry out an efficient
ubiquitination of AMPK subunits, whereas it was active in
promoting the ubiquitination of its known substrate p53
(Figure 1D). Together, all these results indicate that the
laforin–malin complex can promote the selective ubiquitina-
tion of the three individual AMPK subunits tested.
We extended our analysis to other isoforms of AMPK
subunits, such as AMPK1 and AMPK1. The laforin–malin
complex could also promote the ubiquitination of these sub-
units (Supplemental Figure S1). We next attempted to map
the regions in AMPK2 involved in the laforin–malin-de-
pendent ubiquitination. We constructed two truncated
forms of AMPK2, one form containing an N-terminal frag-
ment (residues 1–312), comprising the catalytic domain
(KD); and another form containing a C-terminal fragment
(residues 313–552), comprising the regulatory domain (RD)
involved in binding to the AMPK and - subunits. Previ-
ous structural analysis indicated that both forms are able to
form a stable fold (Sanz, 2008). However, when we ex-
pressed these truncated forms, we did not observe any
efficient laforin–malin-dependent ubiquitination (Supple-
mental Figure S1). These results suggest that both the KD
and RD domains of AMPK2 are needed to form a motif
competent to be ubiquitinated by the laforin–malin complex.
We also attempted a mapping analysis of the AMPK2
subunit. We constructed two truncated forms, one form
containing the N-terminal region (residues 1–185), including
the GBD; and another form containing the C-terminal region
(residues 186–271), containing the so called “association
with Snf1 complex domain” (ASC), involved in binding to
both AMPK and AMPK subunits. Previous structural
analysis indicates that both forms are able to form a stable
fold (Sanz, 2008). However, when we expressed these trun-
cated forms, we only detected traces of modified products in
the case of the ASC construct, and these were much less
abundant than using full-length AMPK2 (Supplemental
Figure S1). These results suggest that both segments of the
AMPK2 subunit are required to form a motif competent to
be ubiquitinated by the laforin–malin complex.
Next, we checked whether laforin and malin also could
ubiquitinate recombinant AMPK subunits when they were
forming part of a stable trimeric complex. With this aim, we
coexpressed AMPK2, -2, and -1 in cells also expressing
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laforin and malin. As shown in Figure 2A, we did not detect
any modification of the AMPK2 and AMPK1 subunits,
but the AMPK2 subunit was still ubiquitinated by the
laforin–malin complex, although to a much lesser extent
than when it was expressed individually (Figure 2A). We
also analyzed the laforin–malin-dependent ubiquitination of
the endogenous AMPK complex. When both laforin and
malin were expressed, only ubiquitination of the endoge-
nous AMPK subunit was detected (Figure 2B). These re-
sults suggest, first, that AMPK and AMPK subunits be-
come poor substrates for the laforin–malin-dependent
ubiquitination when they are part of a stable heterotrimeric
complex; and, second, that AMPK subunits are substrates
for laforin–malin-dependent ubiquitination even when they
are part of a heterotrimeric complex.
To exclude the possibility that the observed modifica-
tion could occur just by having high concentrations of the
laforin–malin complex and substrate proteins, we treated
cells with the proteasomal inhibitor MG132, which in-
duces the accumulation of polyubiquitinated proteins. As
shown in Figure 3A, inhibition of proteasome activity
with MG132 resulted in the accumulation of polyubiquiti-
nated forms of all three individual AMPK subunits tested,
i.e., AMPK2, -2, and -1. Therefore, these individual
subunits could be modified by endogenous E3-ubiquitin
ligases. We also studied whether the AMPK subunits
forming part of the endogenous heterotrimeric complex
were modified by ubiquitination. As shown in Figure 3B,
treatment with MG132 promoted the accumulation of ubi-
quitinated AMPK subunits but had no effect on AMPK
and AMPK subunits. These results suggest that when
AMPK and AMPK subunits form part of a heterotri-
meric AMPK complex, they are less sensitive to ubiquiti-
nation by endogenous E3-ubiquitin ligases. However, the
AMPK subunits remain sensitive to this type of modifi-
cation, whether present as free subunits or within hetero-
trimeric complexes. Because the ubiquitination profile of
AMPK subunits by endogenous E3-ubiquitin ligases was
similar to the one obtained by the expression of laforin
and malin, these results confirmed a positive role of the
laforin–malin complex in the ubiquitination of AMPK
subunits.
Figure 1. The laforin–malin complex is able to
promote ubiquitination of individual AMPK sub-
units. (A) Diagram of the protocol used to deter-
mine the presence of ubiquitinated proteins, based
on the use of a 6xHis-tagged version of ubiquitin
(Kaiser and Tagwerker, 2005). (B) HEK293 cells
were transfected with plasmid pCMV-His6xUbiq
and the indicated combination of plasmids
(pLaforin, pCMV-HA-laforin; and pMalin,
pcDNA3-HA-malin). Cell extracts were then ob-
tained as described inMaterials andMethods and the
clarified extract (CE; 40 g), and the material
bound to the metal-affinity chromatography col-
umn (bound; 40 l) was analyzed by SDS-PAGE
and Western blotting using anti-myc antibodies.
Molecular mass markers are indicated on the left of
each panel. For AMPK2 and AMPK1, we also
detected a minor modification when only laforin
was overexpressed, perhaps because it can force
endogenous malin to carry out the corresponding
ubiquitination. (C) HEK293 cells were transfected
with plasmid pCMV-His6xUbiq and the indicated
combination of plasmids (Mdm2, pCMV-Mdm2;
Laf/Mal, pCMV-HA-laforin/pcDNA3-HA-malin;
and empty, pCMV-HA). Cell extracts were ana-
lyzed as described above using anti-myc antibod-
ies. (D) HEK293 cells were transfected with plas-
mid pCMV-His6xUbiq and plasmids pCMV-p53
and pCMV-Mdm2 or pCMV-HA (empty). Cell ex-
tracts were analyzed as described above using anti-
p53 antibodies.
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Effect of the Laforin–Malin-dependent Ubiquitination on
Protein Stability
We next studied the effect of the laforin–malin-dependent
ubiquitination on protein stability. With this aim, we ex-
pressed individual subunits of AMPK with or without
laforin and malin. Cells were treated with cycloheximide to
inhibit new protein synthesis, and the degradation rates of
the corresponding proteins were measured. In agreement
with published results (Crute et al., 1998), the half-lives of
the individual AMPK subunits (AMPK2, -2, and -1)
were 4–6 h (Figure 4, A–C). Surprisingly, we found that
coexpression of laforin and malin did not accelerate the
degradation of any of the AMPK subunits tested (Figure 4,
A–C). We also analyzed the half-life of the subunits when
they were coexpressed (AMPK2, -2, and -1) and found
that laforin and malin did not change the half-lives of these
proteins either (data not shown). These results suggest that
the laforin–malin-dependent ubiquitination of AMPK sub-
units does not promote their rapid degradation.
During the course of this study, we noticed that the
steady-state levels of AMPK subunits were higher in cells
coexpressing the laforin–malin complex (Figure 4B). We
studied this accumulation in more detail and found, first,
that it was not related to enhanced general transcription/
translation, because the levels of a coexpressed protein such
as green fluorescent protein (GFP), whose expression was
driven by the same promoter as the one found in the
AMPK construct, were unchanged (Figure 4D). Second, in
regular cells the steady-state levels of AMPK2 subunit
increased upon inhibition of either the lysosomal (treatment
with ammonium chloride and leupeptin) or proteasomal
(treatment with lactacystin) pathways (Figure 4E). However,
in the presence of the laforin–malin complex, treatment of
the cells with lysosome or proteasome inhibitors did not
increase the steady-state levels of the AMPK2 subunit (Fig-
ure 4E) (similar results were obtained when we analyzed the
steady-state levels of the AMPK1 subunit; data not shown).
These results indicated that the laforin–malin complex pro-
moted the accumulation of AMPK subunits in forms that
were resistant to their rapid proteolytic turnover.
The action of the laforin–malin complex was therefore
contrary to what has been recently described for the action
of cell death-inducing DFFA-like effector A (CIDEA) that
induced the rapid degradation of AMPK subunits (Qi et al.,
2008). To confirm these two types of action on the same
substrate (AMPK2), we analyzed the steady-state levels of
AMPK2 in cells expressing CIDEA and found, in agree-
ment with a previous report (Qi et al., 2008), that they were
much lower than in control cells (Figure 4F). By contrast, the
expression of laforin and malin resulted in higher steady-
state levels of AMPK2 (Figure 4F). These results indicated
that the modifications induced by CIDEA and by the
laforin–malin complex resulted in opposite effects: whereas
CIDEA decreased the stability of AMPK2, the laforin–ma-
lin complex promoted the long-term accumulation of the
protein.
The Laforin–Malin Complex Introduces K63-Ubiquitin
Chains into Its Corresponding Substrates
To understand why the laforin–malin-dependent ubiquiti-
nation of AMPK subunits did not promote their rapid deg-
radation, we analyzed the topology of ubiquitin chains in-
Figure 2. Laforin–malin-dependent ubiquitination
of the heterotrimeric AMPK complex. (A) Analysis
of overexpressed AMPK complex. HEK293 cells
were transfected with plasmid pCMV-His6xUbiq
and the indicated combination of plasmids (,
pCMVmyc-AMPK2  pCMVmyc-AMPK2  pC-
MVmyc-AMPK1; 2, pCMVmyc-AMPK2; 2, pC-
MVmyc-AMPK2; 1, pCMVmyc-AMPK1; and
pLaf/pMal, pCMV-HA-laforin/pcDNA3-HA-ma-
lin). Cell extracts were analyzed as described in
Figure 1 by using anti-AMPK total, anti-AMPK
total, or anti-AMPK1 antibodies. (B) Analysis of
endogenous AMPK complex. HEK293 cells were
transfected with plasmid pCMV-His6xUbiq and
plasmids pCMV-HA-laforin (pLaf) and pcDNA3-
HA-malin (pMal), when indicated. Cell extracts
were analyzed as described in A but using anti-
AMPK total, anti-panAMPK, and anti-AMPK1
antibodies to determine the components of the en-
dogenous AMPK complex (*, nonspecific band). Mo-
lecular mass markers are indicated on the left of
each panel.
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troduced by this E3-ubiquitin ligase complex. With this aim,
we expressed in HEK293 cells forms of ubiquitin that con-
tained either K48R or K63R mutations, to prevent the assem-
bly of the corresponding ubiquitin chains. Because in the
ubiquitination of AMPK1 the background level was higher
than in AMPK2 and AMPK2 (Figure 1C), we focused our
attention on the modification that suffered only the last two
AMPK subunits. As shown in Figure 5, the laforin–malin
complex produced ubiquitinated forms of AMPK2 and
AMPK2 in the presence of K48R-ubiquitin (Figure 5, A and
B) that were even more abundant than in wild-type ubiq-
uitin, perhaps because of a better efficiency of the laforin–
malin-dependent ubiquitination under these conditions.
However, AMPK2 and AMPK2 did not result signifi-
cantly ubiquitinated in the presence of K63R-ubiquitin (Fig-
ure 5, A and B), indicating that the laforin–malin complex
introduced K63-ubiquitin chains into the AMPK subunits
tested. Crude extracts contained similar amounts of total
ubiquitinated proteins in all the cases which indicated that
the three modified ubiquitins were functional. In addition,
control experiments using the E3-ubiquitin ligase Mdm2
and its substrate p53 demonstrated that the K48R- and
K63R-ubiquitins yielded modified forms of p53 (Figure 5C).
We extended this type of analysis to the ubiquitination of the
PP1 glycogenic targeting subunit R5/PTG, another substrate
of the laforin–malin complex (Solaz-Fuster et al., 2008), and
we found that the complex also promoted the ubiquitination
of R5/PTG by the acquisition of K63-linked ubiquitin chains
(Figure 5D).
To confirm the topology of ubiquitin linkages introduced
by the laforin–malin complex we used an alternative strat-
egy based on the use of antibodies that recognize specifically
K48- and K63-ubiquitin chains (Newton et al., 2008). We ex-
pressed a 6xHis-tagged-AMPK2 fusion protein in HEK293
cells with or without laforin and malin, and we purified the
fusion protein by metal-affinity chromatography. The purified
fractions were then analyzed by Western blotting using an
antibody that recognizes total ubiquitin conjugates and anti-
bodies that specifically recognize K48- and K63-polyubiquitin
conjugates. As expected, coexpression of laforin and malin
induced greater degree of ubiquitination of 6xHis-AMPK2
(assessed using a general antiubiquitin conjugates antibody)
(Figure 5E). This increase in laforin–malin-mediated ubiquiti-
nation was also clearly observed when we used the antibody
that recognized K63-ubiquitin chains (anti-K63) but only to a
very low extent when we used the antibody that recognized
K48-ubiquitin chains (anti-K48).
We also analyzed the topology of ubiquitin chains intro-
duced by the laforin–malin complex on endogenous
AMPK subunits. We found that it also promoted the ac-
quisition of K63-linked ubiquitin chains (Figure 5F).
Figure 3. AMPK subunits accumulate as ubi-
quitinated proteins upon proteasome inhibi-
tion. (A) Analysis of the expression of individ-
ual AMPK subunits. HEK293 cells were
transfected with plasmid pCMV-His6xUbiq
(when indicated) and either pCMVmyc-
AMPK2, pCMVmyc-AMPK2, or pCMV-
myc-AMPK1. Eighteen hours after transfec-
tion, cells were treated with or without 50 M
MG132 and incubated 18 h further. Cell ex-
tracts were then analyzed as described in Fig-
ure 1 by using anti-myc antibodies. (B) Anal-
ysis of the subunits of the endogenous AMPK
complex. HEK293 cells were transfected only
with plasmid pCMV-His6xUbiq (when indi-
cated) and analyzed as described in A but
using anti-AMPK total, anti-panAMPK, and
anti-AMPK1 antibodies to determine the
components of the endogenous AMPK com-
plex (*, nonspecific band). Molecular mass
markers are indicated on the left of each panel.
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We extended our analysis to the ubiquitination that suf-
fered AMPK2 subunit by endogenous E3-ubiquitin ligases
(Figure 6). We observed that treatment of cells expressing
AMPK2 subunit with MG132 resulted in an accumulation
of polyubiquitinated forms, which were more evident if the
cells were expressing K48R-ubiquitins. However, in the
presence of K63R-ubiquitins, no polyubiquitinated forms of
AMPK2 were detected even in the presence of MG132.
Crude extracts contained similar amounts of total ubiquiti-
nated proteins in MG132 treated or untreated cells, respec-
tively. These results indicate that endogenous E3-ubiquitin
ligases also promote the acquisition of K63-linked ubiquitin
chains into AMPK2 subunits.
Effect of the Laforin–Malin-dependent Ubiquitination on
AMPK Function and Localization
We analyzed next the effect of the laforin–malin-dependent
ubiquitination on the function of the AMPK complex. The
activity of the whole AMPK complex was measured by its
capacity to phosphorylate acetyl-CoA carboxylase (ACC),
one of its specific substrates. However, we did not detect
any difference in either HEK293 or HeLa (data not shown)
cells when we coexpressed or not laforin and malin: the
basal phosphorylation status of ACC was similar in all the
cases and its phosphorylation was induced to similar levels
upon treatment with the AMPK activator phenformin (Sup-
plemental Figure S2). We also assayed whether the defi-
ciency in laforin could affect the expression or activation of
the endogenous AMPK complex. With this aim we used a
mouse model of Lafora disease, deficient in the expression of
laforin (Epm2a/) (Ganesh et al., 2002). Our results indi-
cate that in the absence of laforin, the levels of endogenous
AMPK and AMPK subunits and the regulation of
AMPK-Thr172 phosphorylation in liver and brain of
Epm2a/mice are similar to control animals (Supplemen-
tal Figure S3).
We also analyzed the subcellular distribution of AMPK
subunits upon treatment with the laforin–malin complex, as
a possible way to regulate AMPK function (Figure 7). The
expression of AMPK2 subunit resulted in a punctuated
distribution of the protein throughout the cell, although it
was less abundant within the nucleus (Figure 7A). However,
the coexpression of laforin and malin produced some dis-
tinct inclusion bodies (sometimes perinuclear), which con-
Figure 4. Degradation rates of individual AMPK sub-
units in the presence or absence of the laforin–malin
complex. HEK293 cells were transfected with plasmid
pCMVmyc-AMPK2 (A), pCMVmyc-AMK2 (B), or
pCMVmyc-AMPK1 (C) without or with a combination
of plasmids pCMV-HA-laforin and pcDNA3-HA-ma-
lin. Twenty-four hours after transfection, cells were
treated with 355 M CHX, and at the indicated times,
aliquots were taken from the cultures and cell extracts
(25 g) were analyzed by SDS-PAGE and Western blot-
ting using anti-myc antibodies. The same blots were
analyzed using anti-tubulin antibodies as loading con-
trols. A representative blot is shown in A, B, and C. M,
molecular mass standards lane. The right of each panel
shows a plot of the levels of the corresponding myc-
AMPK subunit with respect to the levels of tubulin of
each time point, expressed as a percentage of the value
at time 0. Plots are the mean of three different experi-
ments (bars are SD). (D) The laforin–malin complex
increases the steady-state levels of AMPK subunits.
HEK293 cells were cotransfected with plasmid pCMV-
GFP, and pCMVmyc-AMPK1 or pCMVmyc-AMPK2
and a combination or not of plasmids pCMV-HA-
laforin and pcDNA3-HA-malin (L/M; empty: pCMV-
HA). After 24 h of transfection, cell extracts (30 g) were
analyzed by SDS-PAGE and Western blotting using
anti-AMPK (top) and anti-GFP (bottom) antibodies.
(E) HEK293 cells cotransfected with plasmid pCMV-
myc-AMPK2 and a combination or not of plasmids
pCMV-HA-laforin and pcDNA3-HA-malin (pLaforin 
pMalin). After 18 h of transfection, cells were treated for
5 h with either 20 mM ammonium chloride and 100 M
leupeptin (to inhibit lysosomes) or with 5 M lactacys-
tin (to inhibit proteasomes) or left untreated (Untr). Cell
extracts (30 g) were then analyzed by SDS-PAGE and
Western blotting using anti-myc (top) and anti-tubulin
(bottom) antibodies. (F) CIDEA and the laforin–malin
complex have opposite effects on AMPK2 accumu-
lation. HEK293 cells were transfected with plasmid
pCMVmyc-AMPK2 and with plasmids pFLAG-CIDEA
or pCMV-HA-laforin and pcDNA3-HA-malin (Laf/Mal)
or with an empty plasmid (pCMV-HA). Then, cell extracts
(30 g) were analyzed by SDS-PAGE and Western blot-
ting using anti-myc (top) and anti-tubulin (bottom) anti-
bodies.
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tained laforin and AMPK2 (Figure 7B; 38% of cells trans-
fected with AMPK2, laforin, and malin contained these
inclusions, Figure 7E). Localization analysis of AMPK1
subunit gave similar results (data not shown). These inclu-
sion bodies contained ubiquitin as they were stained with
anti-ubiquitin antibodies (Figure 7C). However, the pres-
ence of these aggregates diminished if we transfected the
cells with a K63R-ubiquitin–expressing plasmid (Figure 7D;
only 14% of cells expressing AMPK2 contained the inclu-
sions, Figure 7E). All these results suggested that the laforin–
malin complex promoted the formation of inclusion bodies
containing at least AMPK2, laforin, and ubiquitin, by in-
troducing K63-linked ubiquitin chains into the correspond-
ing substrates.
DISCUSSION
We report in this study that a functional complex formed by
laforin, a dual-specificity protein phosphatase, and malin, an
E3-ubiquitin ligase, related to Lafora disease, promotes the
ubiquitination of AMPK subunits. This reaction occurs
when any of the three AMPK subunits (, , and ) are
expressed individually in cells, but it also occurs on AMPK
subunit when it is part of a heterotrimeric AMPK complex.
The different ability of AMPK and AMPK to be ubiquiti-
nated by the laforin–malin complex depending on whether
they are forming part or not of a trimeric complex could be
due to different folding. It has been described that when
AMPK subunits are forming part of a heterotrimeric com-
plex they have a longer half-life than when they are ex-
pressed individually (12–13 h instead of 5–6 h) (Crute et al.,
1998). Perhaps subunits forming part of a complex have
specific domains less exposed to modifier enzymes because
they participate in the interaction with other subunits. The
reaction needs both components of the laforin–malin com-
plex, where laforin has been previously shown to function
by recruiting putative substrates to be modified by the E3-
ubiquitin ligase activity of malin. These results complement
previous findings of our group that indicated that laforin
was able to interact physically with different subunits of the
AMPK complex (Solaz-Fuster et al., 2008). Because a similar
ubiquitination profile of AMPK subunits was detected when
we treated cells with the proteasome inhibitor MG132, we
suggest that laforin and malin may form part of a collection
of endogenous E3-ubiquitin ligases that are responsible for
the ubiquitination of AMPK subunits.
We studied in more detail the topology of the linkages
present in the polyubiquitin chains of the modified AMPK
subunits. We used two different strategies: the use of mu-
tated forms of ubiquitin, i.e., K48R and K63R, and the use of
antibodies that recognize specific type of polyubiquitin
chains. We found that the laforin–malin complex promotes
the formation of K63-linked ubiquitin chains in AMPK sub-
units. The same topology was found in the ubiquitination of
Figure 5. The laforin–malin complex pro-
motes the formation of K63-linked ubiquitin
chains into its corresponding substrates.
HEK293 cells were transfected with plasmids
pCMVmyc-AMPK2 (A), pCMVmyc-
AMPK2 (B), or pCMVmyc-R5/PTG (D), and
pCMV-HA-laforin, pcDNA3-HA-malin and ei-
ther pCMV-His6xUbiq (WT), pCMV-
His6xUbiq K48R (K48R), or pCMV-His6xUbiq
K63R (K63R). Cell extracts were analyzed as
described in Figure 1 using anti-myc antibod-
ies. (C) HEK293 cells were transfected with
plasmids pCMV-p53, pCMV-Mdm2, and ei-
ther pCMV-His6xUbiq (WT), pCMV-
His6xUbiq K48R (K48R), or pCMV-His6xUbiq
K63R (K63R). Cell extracts were analyzed as
described in Figure 1 by using anti-p53 anti-
bodies. Molecular mass markers are indicated
on the left of each panel. Total ubiquitinated
proteins were analyzed in the crude
extracts (40 g) of each panel by using anti-
ubiquitin conjugates antibodies. (E) His-
AMPK2 is also modified with K63-ubiquitin
linkages by the laforin–malin complex.
HEK293 cells were transfected with plasmid
pcDNA4/His-AMPK2 (6xHis-AMPK2)
with or without plasmids pCMV-HA-laforin
and pcDNA3-HA-malin (pLaf/pMal). Cell ex-
tracts were prepared as described in Figure 1,
and the bound material was analyzed using
antibodies against conjugated ubiquitin (anti-
ubiq), K48-linked poly-ubiquitin (anti-K48), or
K63-linked poly-ubiquitin (anti-K63) chains.
CEs (40 g) also were analyzed using anti-
AMPK antibodies. (F) Ubiquitination of en-
dogenous AMPK subunits. HEK293 cells
were transfected with plasmids pCMV-HA-
laforin, pcDNA3-HA-malin, and either pCMV-
Ubiqx6His (WT), pCMV-Ubiqx6His K48R
(K48R), or pCMV-Ubiqx6His K63R (K63R).
Cell extracts were analyzed as described in A:
the bound material and CE (40 g) were ana-
lyzed using anti-pan AMPK antibodies.
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AMPK promoted by endogenous E3-ubiquitin ligases (Fig-
ure 6). These results indicated that only E3-ubiquitin ligases
with the specificity of promoting K63-ubiquitination are able
to modify AMPK subunits. In addition, a similar topology
of ubiquitin linkages was introduced by the laforin–malin
complex into R5/PTG, another substrate of the complex
(Solaz-Fuster et al., 2008). All these results indicate that the
laforin–malin complex has the specificity of introducing
K63-linked ubiquitin chains into its corresponding sub-
strates. We do not know yet the E2-conjugating enzyme that
participates in this reaction. So far, it has been described that
malin can promote an efficient ubiquitination when is asso-
ciated with the E2 UbcH2, UbcH5, and UbcH6 (Gentry et al.,
2005; Solaz-Fuster et al., 2008), although all these results
were obtained in vitro. Recently, it has been proposed that
the U-box cochaperone carboxyl terminus of the Hsc70-
interacting protein (CHIP) stabilizes malin (Rao et al., 2010).
Because CHIP may interact with the E2 UbcH13/Uev1a, a
heterodimeric E2 enzyme that exclusively forms K63-linked
ubiquitin chains (Windheim et al., 2008; Xu et al., 2008), we
suggest that laforin and malin could form a macrocomplex
with CHIP and UbcH13/Uev1a that would be responsible
for the K63-linked ubiquitination of specific substrates. In
this way, malin would resemble parkin, an E3-ubiquitin
ligase related to Parkinson disease, because it was described
that parkin mediated the K63-linked ubiquitination of mis-
folded DJ-1 (Olzmann et al., 2007), synphilin-1 (Lim et al.,
2005), and -synuclein (Liu et al., 2007), promoting in this
way their aggregation, and that the action of parkin was
possibly mediated by its interaction with CHIP and
UbcH13/Uev1a [(Lim et al., 2006), (Yoshida, 2007), (Kostova
et al., 2007)]. Alternatively, laforin and malin could interact
directly with UbcH13/Uev1a.
Although our results suggest that the laforin–malin com-
plex introduces K63-linked ubiquitin chains into its corre-
sponding substrates, we do not discard the possibility that
under certain circumstances, it could also promote the for-
mation of K48-linked ubiquitins. This possibility also has
been recently described for parkin that in addition to
modifying synphilin-1 by K63-linked ubiquitin chains, also
mediates the proteasomal degradation of this protein by
introducing K48-linked ubiquitin chains, but only at an un-
usually high parkin-to-synphilin-1 expression ratio or when
Figure 6. Endogenous E3-ubiquitin ligases also promote the K63-
linked ubiquitination of AMPK2. HEK293 cells were transfected
with plasmid pCMVmyc-AMPK2 and either pCMV-His6xUbiq
(WT), pCMV-His6xUbiq K48R (K48R), or pCMV-His6xUbiq K63R
(K63R). Eighteen hours after transfection, cells were treated with or
without 50 M MG132 and incubated 18 h further. Cell extracts
were then analyzed as described in Figure 1 by using anti-myc
antibodies. Total ubiquitinated proteins were analyzed in the crude
extracts (40 g) of each panel by using anti-ubiquitin conjugates
antibodies.
Figure 7. The laforin–malin complex promotes the aggregation of
coexpressed AMPK subunits. (A–D) HEK293 cells were transfected
with plasmid pCMVmyc-AMPK2 with (B and C) or without (A)
plasmids pCMV-HA-laforin and pcDNA3-HA-malin (LafMal).
When indicated, cells were also transfected with plasmid pCMV-
His6xUbiq K63R (D). The subcellular localization of AMPK2 subunit
was carried out as described in Materials and Methods by using anti-
AMPK total as primary and anti-rabbit Alexa-Fluor 488 as secondary
antibodies. The same samples were treated with Topro3 to stain the
nucleus and with anti-laforin or anti-ubiquitin as primary and anti-
mouse Texas Red as secondary antibodies to determine the localization
of laforin and ubiquitin conjugates. The three images were subjected to
a merge analysis. (E) Quantification of cells expressing AMPK2 and
showing either a punctuated distribution or large inclusion bodies.
One hundred cells expressing AMPK2 from each of the above con-
ditions were used to estimate the proportion of cells with or without
inclusions. Bars indicate SD; statistical significance was considered at
*p  0.05 and **p  0.01.
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primed with K48-linked ubiquitination (Lim et al., 2005).
Perhaps this is the reason why the overexpression of laforin
and malin could promote the proteasomal degradation of
R5/PTG (Solaz-Fuster et al., 2008). In this sense, the results
presented in Figure 5, A and B, might underestimate a
possible ubiquitination of AMPK subunits by K48-linked
ubiquitins that would be absent in the K63R lanes because of
their rapid proteasomal degradation. However, the impor-
tance of this possible modification must be very low because
no differences in the degradation rates of AMPK subunits
were observed in the presence or absence of the laforin–
malin complex.
Consistent with the idea that K63-linked polyubiquitin
chains are not involved in protein degradation but in other
intracellular signaling functions (Ikeda and Dikic, 2008; De-
shaies and Joazeiro, 2009), we found that the laforin–malin-
dependent ubiquitination of AMPK subunits did not accel-
erate their rapid proteolytic degradation (Figure 4). On the
contrary, the laforin–malin-dependent ubiquitination of at
least AMPK subunits resulted in an increase of the steady-
state levels of these proteins. Recently, it was reported that
CIDEA promotes the ubiquitination and subsequent degra-
dation of AMPK subunits (Qi et al., 2008). Because CIDEA
is not itself an E3-ubiquitin ligase, the authors suggested
that, by binding to AMPK, CIDEA could recruit specific
E3-ubiquitin ligases that would ubiquitinate AMPK, tar-
geting it for proteasomal degradation. The authors did not
study the type of polyubiquitin chains that CIDEA pro-
moted on AMPK, but we suspect that they must be differ-
ent from the K63-linkages that the laforin–malin complex is
able to produce. As a result, whereas CIDEA-promoted ubiq-
uitination of AMPK enhanced the degradation of the subunit,
the laforin–malin-promoted ubiquitination of AMPK resulted
in its accumulation. In CIDEA-induced ubiquitination, the au-
thors mapped the domain that was involved in this modifica-
tion at the C terminus of AMPK (residues 231–248) (Qi et al.,
2008). We constructed similar truncated forms of AMPK2 as
those reported in the study of CIDEA (Qi et al., 2008). However,
this modification was abolished when either the N-terminal
(residues 1–185) or the C-terminal (residues 186–271) part of
the protein was used in the assay, compared with the full-
length AMPK subunit. These results suggest that the ubiq-
uitination induced by CIDEA and by the laforin–malin com-
plex must depend on different lysine residues of the AMPK
subunit.
The laforin–malin-dependent K63-linked polyubiquitina-
tion of AMPK subunits has no apparent effect on AMPK
activity. However, we observed that cells coexpressing
laforin, malin, and AMPK subunits produced inclusion
bodies that were positive for at least ubiquitin, laforin, and
AMPK (Figure 7). The overexpression of laforin and malin
was the trigger for the formation of these protein inclusions,
in agreement with their aggregation prone capabilities (Mit-
tal et al., 2007; Liu et al., 2009; Rao et al., 2010), because when
laforin and malin were not coexpressed no inclusion bodies
were formed. The fact that the presence of these aggregates
diminished if the cells coexpressed K63R-ubiquitin suggests
that K63-linked ubiquitination of AMPK subunits could be
relevant to form the inclusion bodies. This would be in
agreement with previous results that indicated that K63-
linked ubiquitination favors the formation of protein aggre-
gates (Lim et al., 2005; Tan et al., 2008). Therefore, two pools
of AMPK might coexist in the cells, one pool forming part
of these intracellular inclusions, and another pool that
would be soluble. The pool of AMPK subunits present in
these inclusion bodies would remain less accessible to rapid
proteolytic degradation and this would be the reason of the
observed increase in the steady-state levels of these proteins.
The rest of AMPK would remain in the soluble fraction
displaying its regular function (i.e., ACC phosphorylation).
This increase is however absent in endogenous AMPK
subunits upon treatment with laforin and malin. Perhaps the
levels of modified AMPK subunits required a minimal
concentration to initiate the formation of these intracellular
inclusions and this minimum could not be reached with the
endogenous AMPK subunits.
In summary, our results indicate that the laforin–malin
complex promote the K63-linked ubiquitination of several
substrate proteins and reinforces the idea that Lafora disease
should be considered as a disorder of protein clearance
(Delgado-Escueta, 2007). In the absence of a functional
laforin–malin complex unmodified substrates would accu-
mulate, which could eventually affect the unfolded protein
response pathway, the proteasome activity (already de-
scribed in Vernia et al., 2009) and possibly autophagy.
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